The medicinal potential of marijuana is well documented in North America also--in 1860, for example, the convection of the Committee on Cannabis Indica of the Ohio State Medical Society reported on cannabis' therapeutic applications in treating a vast number of ailments, including: mania, whooping cough, asthma, chronic bronchitis, tetanus, epilepsy and withdrawal from alcohol.
Between the years of 1840 and 1860, more than 100 articles were published in the medical community recommending it for various disorders.
Although the extent of the medicinal value of cannabis is debated by some, well-documented beneficial effects have been published over thousands of years. Among these are: the amelioration of nausea and vomiting, stimulation of hunger, (in particular in chemotherapy/ AIDS patients), lowered intraocular eye pressure (shown to be effective for treating glaucoma), as well as general analgesic effects (pain reliever), and the list goes on.
Highly obscured, (until the interent), yet even more remarkable, is mounting evidence showing that cannabis may CURE a variety of conditions including cancer, multiple sclerosis, diabetes, and depression.
On October 7, 2003 a patent entitled "Cannabinoids as Antioxidants and Neuroprotectants" (Patent No. #6,630,507) was awarded to the United States Department of Health and Human Services, based on research done at the National Institute of Mental Health (NIMH), and the National Institute of Neurological Disorders and Stroke (NINDS).
This patent claims that cannabinoids are "useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases." It states that this 'new found' property makes cannabinoids useful in the treatment and prophylaxis of wide variety of ailments.
"The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and HIV dementia." Synthetic cannabinoids are marketed as Marinol in the United States and Germany, and Cesamet in Canada.
On 19 October 2009 the US Deputy Attorney General issued a US Department of Justice memorandum to "All United States Attorneys" providing clear clarification and guidance to federal prosecutors in US States that have enacted laws authorizing the medical use of marijuana and recommending against prosecuting patients using medical cannabis products according to state laws.
Posts
Comments
No comments:
Post a Comment